EGF receptor expression, regulation, and function in breast cancer

Breast Cancer Research and Treatment

Volumn 29, Issue 1, 1994, Pages 29-40

  Chrysogelos, Susan A ^a,b   Dickson, Robert B ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

c erbB 2; c myc; EGF receptor gene; estrogen receptor; oncogenes; phosphorylation; promoter; signal transduction; TGF

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; PHORBOL ESTER; RECEPTOR PROTEIN; STEROID HORMONE; TRANSFORMING GROWTH FACTOR ALPHA;

BREAST CANCER; BREAST CARCINOGENESIS; CELL ONCOGENE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMAN; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; REGULATORY SEQUENCES, NUCLEIC ACID; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR MARKERS, BIOLOGICAL;

EID: 0028266876     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/BF00666179     Document Type: Editorial

References (126)

1. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen and progestin receptor levels
2. Epidermal growth factor receptors and oestrogen receptors in human breast cancers
3. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer
4. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines
5. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptorpositive human primary breast cancers
6. Epidermal growth factor receptor in breast cancer. Comparison with non-malignant breast tissue
7. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo
8. Double immunocytochemical assay of receptors for oestrogen (ER) and epidermal growth factor (EGFR)
9. Growth factor expression in normal, benign, and malignant breast tissue
10. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma
11. Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study
12. Epidermal growth factor receptors in cancer tissues of esophagus, lung, pancreas, colorectum, breast and stomach
13. Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast
14. Epidermal growth factor receptor and oestrogen receptors in the non-malignant part of the cancerous breast
15. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues
16. neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues
17. Characterization of normal breast epithelial cells in primary cultures: differentiation and growth factor receptors studies
18. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
19. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines
20. Human tumor cell lines with EGF receptor gene amplification in the absence of aberrant sized mRNAs
21. The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription
22. Epidermal growth factor stimulates the synthesis of its own receptor in a human breast cancer cell line
23. Epidermal growth factor receptor synthesis is stimulated by phorbol ester and epidermal growth factor
24. Epidermal growth factor regulates the expression of its own receptor
25. Transcriptional regulation of proto-oncogene expression by epidermal growth factor, transforming growth factor β1, and triiodothyronine in MDA-468 cells
26. Modulation of transforming growth factor alpha-dependent expression of epidermal growth factor receptor gene by transforming growth factor beta, triiodothyronine, and retinoic acid
27. Post-transcriptional destablization of estrogen receptor mRNA in MCF-7 cells by TPA
28. Modulation of estrogen receptor and epidermal growth factor receptor mRNAs by phorbol ester in MCF-7 breast cancer cells
29. Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines
30. Regulation of epidermal growth factor receptor by estrogen
31. Estrogen regulation of epidermal growth factor receptor messenger ribonucleic acid
32. Progestin regulation of EGF-receptor mRNA accumulation in T47D human breast cancer cells
33. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells
34. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites
35. 1,25-dihydroxyvitamin D3 inhibits the clonogenic growth of transformed cells via its receptor
36. 1,25-dihydroxyvitamin D3 increases epidermal growth factor receptor gene expression in BT-20 breast carcinoma cells
37. 1,25-dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20)
38. Thyroid hormone regulation of epidermal growth factor receptor levels in mouse mammary glands
39. Regulation of epidermal growth factor receptor levels by thyroid hormone
40. Ligandactivated thyroid hormone and retinoic acid receptors inhibit growth factor receptor promoter expression
41. Thyroid hormone decreases the expression of epidermal growth factor receptor
42. Regulation of epidermal growth factor receptor gene expression by retinoic acid and epidermal growth factor
43. Regulation of epidermal growth factor receptor gene expression
44. Transcriptional control of epidermal growth factor receptor by retinoic acid
45. Identification and characterization of a regulated promoter element in the epidermal growth factor receptor gene
46. Contributory effects of de novo transcription and premature transcript termination in the regulation of human epidermal growth factor receptor proto-oncogene RNA synthesis
47. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
48. Epidermal growth factor receptor gene promoter. Deletion analysis and identification of nuclear protein binding sites
49. Epidermal growth factor (EGF) receptor gene transcription. Requirement for Spl and an EGF receptor-specific factor
50. A transcription factor active on the epidermal growth factor receptor gene
51. Isolation and characterization of DNA-binding factors regulating transcription of the EGF receptor protooncogene
52. Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene
53. Molecular cloning and characterization of a human DNA binding factor that represses transcription
54. Cooperative function of two separate enhancers of the human epidermal growth factor receptor protooncogene
55. Regulation of the EGFR gene in breast cancer cell lines: chromatin structure analysis reveals the involvement of intron 1 sequences
56. Anti EGF-receptor antibodies inhibit the autocrine stimulated growth of MDA-MB-468 human breast cancer cells
57. Expression of the transforming growth factor-α/epidermal growth factor receptor pathway in normal human breast epithelial cells
58. Stromal influences on transformation of human mammary epithelial cells overexpressing c-myc and SV40T
59. Epidermal growth factor-dependent transformation by a human EGF receptor proto-oncogene
60. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH3T3 cells
61. Autocrine interaction between TGFα and the EGF-receptor: quantitative requirements for induction of the malignant phenotype
62. Overexpression of epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype
63. The effects of a constitutive expression of transforming growth factor alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo
64. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells
65. Characterization of MCF-7 breast carcinoma cells singly or doubly transfected with c-erbB2 and EGFR
66. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interaction with neu
67. Hetero-dimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation
68. p185-c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases
69. Additive effects of c-erbB2, c-Ha-ras and transforming growth factor α genes in the in vitro transformation of human mammary epithelial cells
70. Clonal cosegregation of tumorigenicity with overexpression of c-myc and transforming growth factor α genes in chemically transformed rat liver epithelial cells
71. Linkage of early onset familial breast cancer to chromosome 17q21
72. Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression
73. Stromal-epithelial interactions in breast cancer
74. Tyrosine phosphorylation and the regulation of cell growth: growth factor-stimulated tyrosine phosphorylation of phospholipase C
75. A signal chain of events
76. The juxtamembrane regions of the EGF receptor and gp185-erbB2 determine the specificity of signal transduction
77. Signal transduction by receptors with tyrosine kinase activity
78. Evidence for epidermal growth factor (EGF)-induced intermolecular antophosphorylation of the EGF receptors in living cells
79. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants
80. The assembly of signalling complexes by receptor tyrosine kinases
81. Triggering signalling cascades by receptor tyrosine kinases
82. Receptor tyrosine kinase substrates: src homology domains and signal transduction
83. Elevated membrane association of phospholipase C-γ1 in MDA-468 mammary tumor cells
84. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases
85. The mitogen-activated protein kinase signal transduction pathway
86. Proteins with SH2 domains: transducers in the tyrosine kinase signaling pathway
87. Control of transcription factors by signal transduction pathways: the beginning of the end
88. Signal integration at the level of protein kinases, protein phosphatases and their substrates
89. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling
90. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1
91. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation
92. How receptors turn Ras on
93. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras
94. Ras activation by insulin and epidermal growth factor through enhanced exchange of guanine nucleotides on p21ras
95. Regulators and effectors of ras proteins
96. Human Sos 1: a guanine nucleotide exchange factor for Ras that binds to GRB2
97. The epidermal growth factor receptor phosphorylates GTPase-activating protein (GAP) at Tyr-460, adjacent to the GAP SH2 domains
98. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases
99. Raf functions downstream of Ras1 in the sevenless signal transduction pathway
100. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1
101. Epidermal growth factor (EGF) stimulates association and kinase activity of Raf-1 with the EGF receptor
102. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro
103. Raf-1 activates MAP kinase-kinase
104. A divergence in the MAP kinase regulatory network defined by MEK kinase and RAF
105. Activation of mitogen-activated protein kinase kinase by v-raf in NIH 3T3 cells and in vitro
106. Complexes of Ras-GTP with Raf-1 and mitogen-activated protein kinase
107. p70s6k function is essential for G1 progression
108. The MAP kinase cascade is essential for diverse signal transduction pathways
109. Nuclear proto-oncogenes FOS and JUN
110. Function of the c-Myc oncoprotein
111. Multiple signal transduction pathways mediate c-Jun protein phosphorylation
112. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max
113. The role of p34 kinases in the G1 to S-phase transition
114. Mechanisms of p34cdc2 regulation
115. Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation
116. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression
117. Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer
118. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer
119. Growth factor stimulation of proliferating cell nuclear antigen (PCNA) in human breast epithelium in organ culture
120. Cyclins and Cancer
121. Oncogenic conversion by regulatory changes in transcription factors
122. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer
123. Redundant cyclin over-expression and gene amplification in breast cancer cells
124. Role of polyunsaturated fatty acids as signal transducers: amplification of signals from growth factor receptors by fatty acids in mammary epithelial cells
125. Rapid effects of EGF on cytoskeletal structures and adhesive properties of highly metastatic rat mammary adenocarcinoma cells